MCID: SPL018
MIFTS: 44

Splenomegaly malady

Categories: Rare diseases

Aliases & Classifications for Splenomegaly

Summaries for Splenomegaly

MalaCards based summary : Splenomegaly is related to hypertriglyceridemia and splenomegaly, cytopenia, and vision loss. An important gene associated with Splenomegaly is JAK2 (Janus Kinase 2), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Praziquantel and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include spleen, bone and bone marrow.

Wikipedia : 71 Splenomegaly is an enlargement of the spleen. The spleen usually lies in the left upper quadrant (LUQ)... more...

Related Diseases for Splenomegaly

Diseases related to Splenomegaly via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 254)
id Related Disease Score Top Affiliating Genes
1 hypertriglyceridemia 29.1 APOE GBA
2 splenomegaly, cytopenia, and vision loss 12.1
3 chronic congestive splenomegaly 12.1
4 myeloid splenomegaly 12.0
5 felty syndrome 11.5
6 sea-blue histiocyte disease 11.4
7 hypersplenism 11.3
8 gaucher's disease 11.2
9 banti's syndrome 11.1
10 hereditary spherocytosis 11.1
11 gray platelet syndrome 11.0
12 prolidase deficiency 11.0
13 zimmermann-laband syndrome 1 11.0
14 persistent polyclonal b-cell lymphocytosis 10.9
15 essential thrombocythemia 10.9
16 autoimmune lymphoproliferative syndrome 10.9
17 wandering spleen 10.9
18 common variable immunodeficiency 10.9
19 autoimmune hemolytic anemia 10.9
20 nodular regenerative hyperplasia 10.9
21 caroli disease 10.9
22 tang hsi ryu syndrome 10.8
23 polycythemia vera, somatic 10.7
24 autoimmune lymphoproliferative syndrome, type iib 10.7
25 autoinflammation with infantile enterocolitis 10.7
26 dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema 10.7
27 b-cell expansion with nfkb and t-cell anergy 10.7
28 thrombocytopenia with beta-thalassemia, x-linked 10.7
29 familial lcat deficiency 10.6
30 glucose phosphate isomerase deficiency 10.6
31 stomatocytosis i 10.6
32 dyserythropoietic anemia, congenital, type ii 10.6
33 brucella canis brucellosis 10.6
34 splenic disease 10.6
35 thalassemia-beta, dominant inclusion-body 10.6
36 littoral cell angioma of the spleen 10.6
37 ras-associated autoimmune leukoproliferative disorder 10.6
38 pseudohyperkalemia cardiff 10.6
39 typhoid fever 10.6
40 myelofibrosis with myeloid metaplasia, somatic 10.6
41 lymphoproliferative syndrome 1 10.6
42 mannosidosis, alpha-, types i and ii 10.6
43 scrub typhus 10.6
44 pdgfrb-associated chronic eosinophilic leukemia 10.6
45 bile acid synthesis defect, congenital, 5 10.6
46 hemophagocytic lymphohistiocytosis, familial, 4 10.6
47 leukemia, chronic myeloid, somatic 10.6
48 leukemia, acute myelomonocytic, somatic, somatic 10.6
49 erythrocytosis due to bisphosphoglycerate mutase deficiency 10.6
50 warm antibody hemolytic anemia 10.6

Graphical network of the top 20 diseases related to Splenomegaly:



Diseases related to Splenomegaly

Symptoms & Phenotypes for Splenomegaly

Drugs & Therapeutics for Splenomegaly

Drugs for Splenomegaly (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Praziquantel Approved, Vet_approved Phase 4 55268-74-1 4891
2 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
3 Anthelmintics Phase 4,Phase 3
4 Antiparasitic Agents Phase 4,Phase 3,Phase 1
5
Lactitol Phase 4 585-86-4 3871
6
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
7
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
8
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
9
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
10
Hydroxyurea Approved Phase 3 127-07-1 3657
11
Busulfan Approved, Investigational Phase 3 55-98-1 2478
12
Anagrelide Approved Phase 3 68475-42-3 2182
13
Vidarabine Approved Phase 3 24356-66-9 32326 21704
14
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
15
Melphalan Approved Phase 3 148-82-3 4053 460612
16
Danazol Approved Phase 3 17230-88-5 28417
17 Alkylating Agents Phase 3,Phase 2,Phase 1
18 Immunoglobulins Phase 3,Phase 2,Phase 1,Early Phase 1
19 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1,Early Phase 1
20 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
21 Antimetabolites Phase 3,Phase 2,Phase 1
22 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
23 Antibodies Phase 3,Phase 2,Phase 1,Early Phase 1
24 Antirheumatic Agents Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
26 glucocorticoids Phase 3,Phase 2
27 Hormone Antagonists Phase 3,Phase 2
28 Hormones Phase 3,Phase 2
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
30 Anti-Inflammatory Agents Phase 3,Phase 2
31 Antimalarials Phase 3,Phase 1
32 Antineoplastic Agents, Hormonal Phase 3,Phase 2
33 Antiprotozoal Agents Phase 3,Phase 1
34 interferons Phase 3
35 Adjuvants, Immunologic Phase 3
36 Nucleic Acid Synthesis Inhibitors Phase 3
37 Pharmaceutical Solutions Phase 2, Phase 3
38 Antiviral Agents Phase 3,Phase 1
39 Vidarabine Phosphate Phase 3
40 Krestin Phase 3
41 6-Mercaptopurine Phase 3
42 tyrosine Nutraceutical Phase 3
43
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
44
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
45
belimumab Approved Phase 2 356547-88-1 5957 10451420
46 Pomalidomide Approved Phase 2 19171-19-8
47
Valproic Acid Approved, Investigational Phase 1, Phase 2 99-66-1 3121
48
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
49
alemtuzumab Approved, Investigational Phase 2 216503-57-0
50
Obinutuzumab Approved Phase 1, Phase 2 949142-50-1

Interventional clinical trials:

(show top 50) (show all 64)
id Name Status NCT ID Phase
1 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4
2 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil Completed NCT00403611 Phase 4
3 CINC424A2X01B Rollover Protocol Recruiting NCT02386800 Phase 4
4 Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis Completed NCT01437787 Phase 3
5 The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia Recruiting NCT02577926 Phase 3
6 Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Recruiting NCT02004691 Phase 2, Phase 3
7 Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting NCT02048813 Phase 3
8 Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency Not yet recruiting NCT03113760 Phase 3
9 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia Terminated NCT02055781 Phase 3
10 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Terminated NCT01773187 Phase 3
11 Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. Terminated NCT02598297 Phase 3
12 Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly Withdrawn NCT01785979 Phase 3
13 Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage Unknown status NCT00949364 Phase 2
14 CEP-701 (Lestaurtinib) in Myelofibrosis Unknown status NCT00668421 Phase 1, Phase 2
15 A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia Unknown status NCT01142011 Phase 2
16 Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly Completed NCT01692366 Phase 2
17 Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia. Completed NCT02049450 Phase 2
18 Phase 2 Study of SAR302503 in Patients With Myelofibrosis Completed NCT01420770 Phase 2
19 Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia Completed NCT00445900 Phase 2
20 Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS) Completed NCT00605657 Phase 1, Phase 2
21 Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia Completed NCT00511069 Phase 2
22 Imatinib Mesylate in Treating Patients With Myelofibrosis Completed NCT00039416 Phase 2
23 Treatment of Polycythemia Vera With Gleevec Completed NCT01120821 Phase 2
24 Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis Completed NCT00586651 Phase 2
25 HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab Completed NCT00349349 Phase 2
26 Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis Recruiting NCT01348490 Phase 2
27 Imetelstat Sodium in Treating Patients With Primary or Secondary Myelofibrosis Active, not recruiting NCT01731951 Phase 2
28 Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia Not yet recruiting NCT02730884 Phase 2
29 Dose-Finding Study of Pacritinib in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib Not yet recruiting NCT03165734 Phase 2
30 Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Not yet recruiting NCT03010358 Phase 1, Phase 2
31 Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera Terminated NCT01038856 Phase 2
32 Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis Terminated NCT00667277 Phase 2
33 Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia Terminated NCT01998828 Phase 2
34 A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL Unknown status NCT00772486 Phase 1
35 A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) Completed NCT00779883 Phase 1
36 A Phase I Extension Trial of Repeated Infusions of ISF35 Completed NCT00783588 Phase 1
37 Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome Completed NCT00013689 Phase 1
38 Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome Completed NCT00065390 Phase 1
39 Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Recruiting NCT02989701 Phase 1
40 Hemolysis in Patients With Hereditary Spherocytosis (HS) Unknown status NCT01201174
41 Microwave Ablation and Partial Splenic Embolization in the Management of Hypersplenism Unknown status NCT02261584
42 Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis Unknown status NCT01201655
43 International Registry for Severe Chronic Neutropenia Unknown status NCT00004342
44 Novel Association of Cholesterol Ester Storage Disease Due to Lysosomal Acid Lipase Deficiency and Non-Alcoholic Fatty Liver Disease: A Prospective Clinical Study Unknown status NCT01791452
45 Relationships Between Mean Plasma Glucose and HbA1c in Cirrhotic Patients With Hepatogenous Diabetes Unknown status NCT02325622
46 Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors Unknown status NCT00933296
47 Estimation of Spleen by Residents With VScan Completed NCT01907932
48 Ultrasound Estimation of Spleen Size Completed NCT01810419
49 Spleen Size in Peripheral Blood Stem Cell Donors Completed NCT00006148
50 Evaluation of a Pocket-Sized Ultrasound Device As an Aid to the Physical Examination Completed NCT01948076

Search NIH Clinical Center for Splenomegaly

Genetic Tests for Splenomegaly

Genetic tests related to Splenomegaly:

id Genetic test Affiliating Genes
1 Splenomegaly 29

Anatomical Context for Splenomegaly

MalaCards organs/tissues related to Splenomegaly:

39
Spleen, Bone, Bone Marrow, Liver, Myeloid, B Cells, T Cells

Publications for Splenomegaly

Articles related to Splenomegaly:

(show top 50) (show all 666)
id Title Authors Year
1
Splenomegaly in the returning traveller: a diagnostic workup. ( 28077481 )
2017
2
Splenomegaly and the JAK2 V617F mutation. ( 27727073 )
2017
3
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. ( 27916398 )
2017
4
FOXP3+ Regulatory T Cells in Hepatic Fibrosis and Splenomegaly Caused by Schistosoma japonicum: The Spleen May Be a Major Source of Tregs in Subjects with Splenomegaly. ( 26731721 )
2016
5
Coxsackie B5 infection in an adult with fever, truncal rash, diarrhea and splenomegaly with highly elevated ferritin levels. ( 27617209 )
2016
6
An Unusual Cause of Splenomegaly. ( 27593911 )
2016
7
Extra pulmonary tuberculosis presenting as fever with massive splenomegaly and pancytopenia. ( 27051579 )
2016
8
Neonatal Jaundice with Splenomegaly: Not a Common Pick. ( 26847548 )
2016
9
An Uncommon Cause of Splenomegaly. ( 27252824 )
2016
10
Notes from the Field: Splenomegaly of Unknown Etiology in Congolese Refugees Applying for Resettlement to the United States - Uganda, 2015. ( 27607133 )
2016
11
Atypical Presentation of CML without splenomegaly. ( 27728298 )
2016
12
JAK2(V617F) allele burden ac350% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy. ( 26975727 )
2016
13
Splenomegaly and thrombosis risk in essential thrombocythemia: the mayo clinic experience. ( 26875150 )
2016
14
A Novel I^-Globin Chain Hemoglobin Variant, Hb Allentown [I^137(H15)Vala89Trp (GTG>TGG) HBB: c.412_413delinsTG, p.Val138Trp], Associated with Low Oxygen Saturation, Intermittent Aplastic Crises and Splenomegaly. ( 26681102 )
2016
15
Three Rwandan Children With Massive Splenomegaly and Epstein-Barr Virus-associated Lymphoproliferative Disorders: Case Presentations and the Literature Review. ( 27352192 )
2016
16
Outcomes of partial splenic embolization in patients with massive splenomegaly due to idiopathic portal hypertension. ( 27920483 )
2016
17
Interesting case of lymphocytosis and splenomegaly. ( 26940880 )
2016
18
Acute Paracoccidioidomycosis Due to Paracoccidioides brasiliensis S1 Mimicking Hypereosinophilic Syndrome with Massive Splenomegaly: Diagnostic Challenge. ( 27054891 )
2016
19
Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX. ( 26790967 )
2016
20
Immunoglobulin-induced hemolysis, splenomegaly and inflammation in patients with antibody deficiencies. ( 26854522 )
2016
21
Splenectomy versus Partial Splenic Embolization for Massive Splenomegaly Secondary to Hepatitis B-Related Liver Cirrhosis: A Case-Control Study. ( 27418925 )
2016
22
Re: Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis. ( 27686082 )
2016
23
A Challenging Case of Splenomegaly and Refractory Thrombocytopenia. ( 26827798 )
2016
24
Rapamycin Attenuates Splenomegaly in both Intrahepatic and Prehepatic Portal Hypertensive Rats by Blocking mTOR Signaling Pathway. ( 26734934 )
2016
25
Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis. ( 27376361 )
2016
26
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. ( 27025789 )
2016
27
Correction: FOXP3+ Regulatory T Cells in Hepatic Fibrosis and Splenomegaly Caused by Schistosoma japonicum: The Spleen May Be a Major Source of Tregs in Subjects with Splenomegaly. ( 26849557 )
2016
28
Laparoscopic versus open splenectomy and devascularization for massive splenomegaly due to portal hypertension. ( 27924505 )
2016
29
Splenic irradiation provides transient palliation for symptomatic splenomegaly associated with primary myelofibrosis: a report on 14 patients. ( 26791378 )
2016
30
Non-FDG Avid Persistent Splenomegaly at Time of Transplantation Delays Neutrophil and Platelets Engraftment Without Affecting Survival in Patients with Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplantation. ( 27660169 )
2016
31
Perioperative spleen embolization as a useful tool in laparoscopic splenectomy for simple and massive splenomegaly in children: a prospective study. ( 26961344 )
2016
32
Selective Spleen Embolization of Splenomegaly to Improve Thrombocytopenia Facilitating Open Aortic Aneurysm Repair: A Staged Approach. ( 27581226 )
2016
33
Splenic irradiation for splenomegaly: A systematic review. ( 28063304 )
2016
34
Safety and effectiveness of total splenic vessel ligations in paediatric patients with splenomegaly. ( 27609328 )
2016
35
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. ( 27416984 )
2016
36
Identification and characterization of avian hepatitis E virus genotype 2 from chickens with hepatitis-splenomegaly syndrome in Korea. ( 27164843 )
2016
37
An interesting case of splenomegaly. ( 27728316 )
2016
38
Tyrosinemia Presenting With Multiple Hepatic Lesions and Splenomegaly. ( 27898518 )
2016
39
Single port laparoscopic splenectomy for wandering spleen with splenomegaly in a patient with Wolf-Hirschhorn syndrome. ( 28000649 )
2016
40
Idiopathic livedo racemosa presenting with splenomegaly and diffuse lymphadenopathy. ( 27874892 )
2016
41
Ultrasound imaging of splenomegaly as a proxy to monitor colon tumor development in Apc(min716/+) mice. ( 27485505 )
2016
42
Case 37-2016. An 86-Year-Old Woman with Leukocytosis and Splenomegaly. ( 27959687 )
2016
43
Chronic malaria and hyper-reactive malarial splenomegaly: a retrospective study on the largest series observed in a non-endemic country. ( 27098596 )
2016
44
Regression of esophageal varices and splenomegaly in two patients with hepatitis-C-related liver cirrhosis after interferon and ribavirin combination therapy. ( 27572075 )
2016
45
Hyper-reactive malarial splenomegaly : A case report. ( 27728705 )
2016
46
A rare presentation of tropical splenomegaly with generalized lymphadenopathy. ( 27728698 )
2016
47
MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia. ( 27768091 )
2016
48
Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly. ( 27672242 )
2016
49
Adaptive splenic radiotherapy for symptomatic splenomegaly management in myeloproliferative disorders. ( 25702680 )
2015
50
Efficacy and surgical procedures of preoperative splenic artery embolization for laparoscopic splenectomy of a massive splenomegaly: A case report. ( 26479782 )
2015

Variations for Splenomegaly

Expression for Splenomegaly

Search GEO for disease gene expression data for Splenomegaly.

Pathways for Splenomegaly

GO Terms for Splenomegaly

Biological processes related to Splenomegaly according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.5 IFNA2 JAK2 MPL
2 negative regulation of inflammatory response GO:0050728 9.49 APOE GBA
3 response to estrogen GO:0043627 9.48 EPO GBA
4 erythrocyte differentiation GO:0030218 9.46 EPO JAK2
5 negative regulation of MAP kinase activity GO:0043407 9.43 APOE GBA
6 response to testosterone GO:0033574 9.4 EPO GBA
7 positive regulation of tyrosine phosphorylation of Stat3 protein GO:0042517 9.37 IFNA2 JAK2
8 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.26 EPO JAK2
9 negative regulation of cellular protein metabolic process GO:0032269 9.16 APOE GBA
10 negative regulation of neuron death GO:1901215 9.13 APOE EPO GBA
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 8.8 EPO IFNA2 JAK2

Sources for Splenomegaly

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....